SCHEMBL30701895

SCHEMBL30701895

CC(C)(C)OC(=O)N1CCC(Oc2ccc3c(=O)[nH]ccc3c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 12/20 0.58
ROCK2 O75116 2/20 0.58
PRKCD Q05655 2/20 0.58
PRKACA P17612 1/20 0.58
PRKG1 Q13976 1/20 0.58
PKN1 Q16512 1/20 0.58
PKN2 Q16513 1/20 0.58
AAK1 Q2M2I8 1/20 0.58
CDC42BPA Q5VT25 1/20 0.58
Q6ZSR9 Q6ZSR9 1/20 0.58
BMP2K Q9NSY1 1/20 0.58
CDC42BPB Q9Y5S2 1/20 0.58
PRKX P51817 1/20 0.52
PRKCE Q02156 1/20 0.52
PRKD1 Q15139 1/20 0.52
GPR119 Q8TDV5 4/20 0.52
ALK Q9UM73 1/20 0.49
CHEK2 O96017 1/20 0.49
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007383 0.88 ROCK1 (0.53) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL4007388 0.88 ROCK1 (0.53) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL12851367 0.87 ROCK1 (0.61) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL3224404 0.85 ROCK1 (0.58) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL12851337 0.83 ROCK1 (0.61) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL28677741 0.83 KDM4E (0.51) GPR119
SCHEMBL3226359 0.83 ROCK1 (0.55) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL31482744 0.83 ROCK1 (0.47) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL3226341 0.83 ROCK1 (0.55) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL2332126 0.82 GPR119 (0.55) GPR119ALKCHEK2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612382-B2 Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound VALO HEALTH INC. (US) 2026-04-28 US disclosed
US-20250296923-A1 PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND VALO HEALTH, INC. (US) 2025-09-25 US disclosed
US-20240287031-A1 PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND VALO HEALTH, INC. (US) 2024-08-29 US disclosed
US-20240287030-A1 PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND VALO HEALTH, INC. (US) 2024-08-29 US disclosed
EP-4402129-A1 <SMALLCAPS/>? ? ?H? ? ? ? ?PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND Valo Health, Inc. (US) 2024-07-24 EP disclosed
WO-2024030854-A1 PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND VALO HEALTH, INC. (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287031-A1 PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND ROCK1, ROCK2, CIT ROCK1 1/4885ROCK2 2/4885PRKCD 302/4885
US-20250296923-A1 PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND ROCK1, ROCK2, CIT ROCK1 1/4885ROCK2 2/4885PRKCD 302/4885
US-12612382-B2 Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound ROCK1, RHOA, ABL1 ROCK1 1/4885ROCK2 7/4885PRKCD 379/4885
US-20240287030-A1 PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND ROCK1, ROCK2, CIT ROCK1 1/4885ROCK2 2/4885PRKCD 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.